Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.

Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.

Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts.

Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents

Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices

Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome

Burgeoning pet care market also presents growth opportunities for VELDONA®

Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots

VELDONA^® low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments